Stage I-III Breast Cancer
Conditions
Brief summary
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
Interventions
None listed
Sponsors
GeneCast Biotechnology Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is ≥ 18 years-old at the time of consent to participate this trial * Patients with stage I-III invasive breast cancer * No prior anti-cancer treatment * Felt to be a possible candidate for neoadjuvant therapy by their physician
Exclusion criteria
* Known to have other aggressive malignant tumor in the past 5 years. * Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators. * There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia. * The investigator determines that subjects are not appropriate to participate in the study due to other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Miller-Payne grading system | 3 years |
| Residual cancer burden (RCB) | 3 years |
Countries
China
Contacts
Primary ContactYunxiang Zhou
Outcome results
None listed